The Motley Fool

Opthea share price lifts on clinical trial update: Is it a spec buy?

The Opthea Ltd (ASX: OPT) share price is up 2.4% to $3.83 today after the eye disease treatment biotech updated investors on progress over its Phase 2b clinical trial into its OPT-302 with ranibizumab (Lucentis®) treatment compared to ranibizumab alone.

According to the company the therapy could be used to treat “wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Wet AMD and DME are leading causes of blindness in the elderly and diabetic populations respectively, and are increasing in prevalence worldwide.”

It also has a number of other Phase I and Phase II clinical trials planned or in progress to develop treatments for eye diseases.

It seems the market is impressed with its chances of commercialisation given the company has a whopping $949 million valuation based on 249.8 million shares on issues and a $3.80 share price.

We can see that the valuation is based almost purely on investor expectation over clinical trial success followed by commercialisation given it made a loss of $20.9 million on revenue of $914,800 in fiscal 2019.

In total it actually made a $35.5 million loss over the year before adding back a $14 million tax benefit to take the net loss to $20.9 million. 

It has no debt and cash on hand of $21.5 million as at period end. 

I’ll admit I know very little about Opthea or its treatments, but I would point out that Phase III trials that Opthea will eventually have to undertake almost always are the largest and most expensive for any biotech research business. 

Bank debt is also generally not an option for businesses with no or immaterial revenue so it’s possible the company will need to go back to the market for more funds in the year or so ahead if it’s to fund Phase III trials and other operations.

Another option is for Opthea to find a large pharmaceutical partner to help wear the cost of the trials in return for some sort of financial interest. 

Another obvious point is that it’s trials offer no guarantee of success (i.e. meeting their primary endpoints) and even if they do there’s no guarantee of commercialisation and profits.

Recently, a company like Sirtex Medial hit the big-time for lucky early-stage investors, but for every Sirtex there are dozens of biotechs that just end up swallowing capital.

Of course if you’re confident you’ve done your research and you’re convinced Opthea is onto a blockbuster commercial breakthrough you can happily ignore my thoughts and buy shares. Clearly, I’m not a buyer of shares myself though.

Other speccy biotechs to consider include the widely-tipped Paradigm Ltd (ASX: PAR), or regenerative medicine business Mesoblast Limited (ASX: MSB).

Our Top 3 Blue Chip Shares for 2019 – NOW AVAILABLE!

You’re invited! For a limited time, The Motley Fool Australia is giving away an urgent new investment report detailing our 3 TOP BLUE CHIP SHARES to own in 2019.

So if you like trustworthy, stable, high-performing companies that pay fat fully franked dividends – we’ve got you covered!

Stock #1 is a beloved old Australian company turning its attention to high-margin businesses... and rapidly returning cash to shareholders with its hefty dividend...

While Stock #2 is an online powerhouse that’s rapidly gaining market share all around the globe... poised for years (or even decades) of tremendous growth...

Even better, Stock #3 offers a whopping 6.5% grossed-up dividend! Which beats the rates on term deposits right out of the water – and offers the potential for capital gains, too.

You can discover all three shares inside our new report right now. To scoop up your FREE copy, simply click the link below right now. But you will want to hurry – this free report is available for a LIMITED TIME ONLY!


Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

FREE REPORT: Five Cheap and Good Stocks to Buy now…

Our Motley Fool experts have FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.7% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.